[Journal logo]

Volume 69 
Part 9 
Page m522  
September 2013  

Received 3 August 2013
Accepted 20 August 2013
Online 23 August 2013

Key indicators
Single-crystal X-ray study
T = 296 K
Mean [sigma](C-C) = 0.003 Å
R = 0.024
wR = 0.069
Data-to-parameter ratio = 12.7
Details
Open access

catena-Poly[[[2-(1,3-thiazol-4-yl)-1H-benzimidazole]manganese(II)]-[mu]-oxalato]

aCollege of Chemistry and Chemical Engineering, Guangxi University for Nationalities, Nanning 530006, People's Republic of China, and bNonferrous Geological Prospecting Bureau, Hunan Non-ferrous Geology Exploration and Institute, Changsha 410015, People's Republic of China
Correspondence e-mail: lplgkt878@163.com

In the title compound, [Mn(C2O4)(C10H7N3S)]n, the MnII cation is chelated by one 2-(1,3-thiazol-4-yl)-1H-benzimidazole ligand and two oxalate anions in a distorted N2O4 octahedral geometry. Two independent oxalate anions are located on individual inversion centers and bridge the MnII cations into a polymeric chain running along [101]. The thiazole ring is approximately coplanar with the benzimidazole ring system [dihedral angle = 4.19 (9)°]. In the crystal, classical N-H...O hydrogen bonds and weak C-H...O hydrogen bonds link the polymeric chains into a three-dimensional supramolecular architecture.

Related literature

For applications of thiabendazole compounds, see: Yu et al. (2002[Yu, X.-Y., Masahiko, M., Tomonori, M., Chang, H.-C., Susumu, K. & Jin, G.-X. (2002). Polyhedron, 21, 1613-1620.]); Devereux et al. (2004[Devereux, M., McCann, M., Shea, D. O., Kelly, R., Egan, D., Deegan, C., Kavanagh, K., McKee, V. & Finn, G. (2004). J. Inorg. Biochem. 98, 1023-1031.]). For related structures, see: Wisniewski et al. (2001[Wisniewski, M.-Z., Glowiak, T., Opolski, A. & Wietrzyk, J. (2001). Met.-Based Drugs, 8, 189-194.]); Jean et al. (2002[Jean, M.-G., Tellez, F., Bernés, S., Nöth, H., Contreras, R. & Barba-Behrens, N. (2002). Inorg. Chim. Acta, 339, 532-542.]).

[Scheme 1]

Experimental

Crystal data
  • [Mn(C2O4)(C10H7N3S)]

  • Mr = 344.21

  • Monoclinic, P 21 /c

  • a = 9.374 (2) Å

  • b = 17.834 (5) Å

  • c = 8.926 (2) Å

  • [beta] = 113.500 (3)°

  • V = 1368.5 (6) Å3

  • Z = 4

  • Mo K[alpha] radiation

  • [mu] = 1.14 mm-1

  • T = 296 K

  • 0.19 × 0.15 × 0.12 mm

Data collection
  • Bruker SMART 1000 diffractometer

  • Absorption correction: multi-scan (SADABS; Bruker, 2001[Bruker (2001). SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.]) Tmin = 0.813, Tmax = 0.876

  • 7273 measured reflections

  • 2412 independent reflections

  • 2221 reflections with I > 2[sigma](I)

  • Rint = 0.017

Refinement
  • R[F2 > 2[sigma](F2)] = 0.024

  • wR(F2) = 0.069

  • S = 1.08

  • 2412 reflections

  • 190 parameters

  • H-atom parameters constrained

  • [Delta][rho]max = 0.27 e Å-3

  • [Delta][rho]min = -0.28 e Å-3

Table 1
Selected bond lengths (Å)

Mn1-O1 2.2146 (15)
Mn1-O2 2.2100 (14)
Mn1-O3 2.1640 (14)
Mn1-O4 2.1667 (15)
Mn1-N1 2.3170 (17)
Mn1-N2 2.2279 (16)

Table 2
Hydrogen-bond geometry (Å, °)

D-H...A D-H H...A D...A D-H...A
N3-H3...O1i 0.86 1.96 2.812 (2) 170
C12-H12...O3ii 0.93 2.52 3.137 (3) 124
Symmetry codes: (i) [x, -y+{\script{3\over 2}}, z-{\script{1\over 2}}]; (ii) -x+1, -y+2, -z.

Data collection: SMART (Bruker, 2007[Bruker (2007). SMART and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.]); cell refinement: SAINT (Bruker, 2007[Bruker (2007). SMART and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.]); data reduction: SAINT; program(s) used to solve structure: SHELXTL (Sheldrick, 2008[Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.]); program(s) used to refine structure: SHELXTL; molecular graphics: SHELXTL; software used to prepare material for publication: SHELXTL.


Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: XU5729 ).


Acknowledgements

The work was supported by the Innovation Project of Guangxi University for Nationalities (gxun-chx2012090).

References

Bruker (2001). SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.
Bruker (2007). SMART and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.
Devereux, M., McCann, M., Shea, D. O., Kelly, R., Egan, D., Deegan, C., Kavanagh, K., McKee, V. & Finn, G. (2004). J. Inorg. Biochem. 98, 1023-1031.  [CSD] [CrossRef] [PubMed] [ChemPort]
Jean, M.-G., Tellez, F., Bernés, S., Nöth, H., Contreras, R. & Barba-Behrens, N. (2002). Inorg. Chim. Acta, 339, 532-542.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.  [CrossRef] [ChemPort] [details]
Wisniewski, M.-Z., Glowiak, T., Opolski, A. & Wietrzyk, J. (2001). Met.-Based Drugs, 8, 189-194.  [ChemPort]
Yu, X.-Y., Masahiko, M., Tomonori, M., Chang, H.-C., Susumu, K. & Jin, G.-X. (2002). Polyhedron, 21, 1613-1620.  [ISI] [CSD] [CrossRef] [ChemPort]


Acta Cryst (2013). E69, m522  [ doi:10.1107/S1600536813023428 ]

This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.